Loading...
Please wait, while we are loading the content...
Similar Documents
Platelet Glycoprotein IIb / IIIa Receptor Inhibitors – Role in Coronary Artery Disease
| Content Provider | Semantic Scholar |
|---|---|
| Author | Neki, N. S. |
| Copyright Year | 2004 |
| Abstract | Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation triggered by endogenous platelet activators. They include agents with varying pharmacodynamic and pharmacokinetic properties. More than 80% inhibition of platelet aggregation is required for effective platelet activity. These drugs have emerged as a valuable adjunct for coronary intervention (PTCA or Stenting) or acute coronary syndromes1. * Professor, Department of Medicine, Government Medical College/GND Hospital, Amritsar-143 001 (Punjab). Introduction Glycoprotein IIb/IIIa receptors present on the surface, numbering about 50-60 thousand per platelet, are responsible for final pathway of platelet aggregation. This platelet aggregation leads to acute vessel closure during percutaneous coronary intervention (PCI), acute coronary syndromes (ACS), acute myocardial infarction (AMI), and restenosis by producing platelet derived growth factor. Gp IIb/IIIa receptors belong to a class of integrins with a specificity for binding to fibrinogen. These receptor blockers have emerged as a valuable adjunct in interventional cardiology. Blocking of these integrin receptors interferes with the final common pathway of platelet aggregation which is mainly responsible for acute coronary syndromes1,2. Classification of GPI 1. Naturally occurring peptide inhibitors (isolated from Viper venoms and Puff adder) – are not used clinically. Examples are (a) Trigramin, (b) Barbourin, (c) Kistrin. 2. Synthetic inhibitors – are of 3 types: i. Monoclonal antibodies: (a) Abciximab – parenteral use; (b) YM337 – parenteral use. ii. Peptide: Eptifibatide – parenteral use. iii. Non-peptide: (a) parenteral use, e.g., tirofiban, lamifiban, fradafiban; (b) Oral use, e.g., xemlofiban, orofiban, sibrafiban, lefradafiban, roxifiban, lotrafiban. Gp IIb/IIIa inhibitors like abciximab, eptifibatide, tirofiban, and lamifiban have been approved by FDA for clinical use. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://medind.nic.in/jac/t04/i3/jact04i3p259.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
